)
)
Edge16 Oct 2026
Winner, Winner: The Chicken McNugget Story
How a 1940s breeding contest, a Cornell food scientist, and a hedge by Ray Dalio helped McDonald's turn the Chicken McNugget into a fast-food icon.
Corbus Pharmaceuticals
Corbus Pharmaceuticals (CRBP) investor relations material
Corbus Pharmaceuticals Q3 2026 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q3 2026 earnings summary10 Nov, 2026
Executive summary
Pipeline centers on sutantatug envedotin for Nectin-4-expressing tumors and CRB-913 for obesity; no product revenue generated to date.
TEMPO-1 began dosing in Phase 3 for 2L+ OPSCC, while CANYON-1 reported positive topline weight-loss results for CRB-913.
Financial highlights
Q3 operating expenses were $38.824M vs. $24.417M YoY; R&D was $34.247M vs. $20.860M and G&A was $4.577M vs. $3.557M.
Q3 net loss was $37.754M vs. $23.342M; 9M net loss was $95.760M vs. $57.982M.
Q3 expense growth was primarily driven by a $15.0M sutantatug envedotin milestone under the CSPC license and higher clinical costs.
9M operating cash use was $76.4M; financing provided $27.6M, mainly through common-stock sales under the Open Market Sale Agreement.
Outlook and guidance
Cash, cash equivalents and investments of $115.3M at Sept. 30, 2026, were expected to fund operations for at least 12 months from filing and into 2028 under current plans.
Sutantatug envedotin plus Keytruda first-line OPSCC data are anticipated in Q1 2027; CRB-913 development plans are to be discussed with FDA, with a potential GLP-1 combination also under evaluation.
Significant expenses and operating losses are expected for several years as clinical and preclinical development, research and manufacturing continue.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from Corbus Pharmaceuticals
- CRB-701 advances in head and neck cancer as CRB-913 pairs weight loss with a differentiated safety profile.CRBP
3rd Annual Guggenheim Healthcare Innovation Conference - CRB-701 oncology results and CRB-913 weight loss lead the clinical pipeline.CRBPCorporate presentation
- Lead assets show promising efficacy in cancer and obesity, with pivotal trials and key data ahead.CRBPCorporate presentation
- CRB-913 achieved 5% mean weight loss at 12 weeks with strong tolerability in obesity trial.CRBPStudy result
- Q2 2026 net loss rose to $35M on higher R&D; cash runway extends into 2028, more funding needed.CRBPQ2 2026
- All proposals, including director elections and compensation matters, were approved by shareholders.CRBPAGM 2026
- Lead oncology and obesity assets advance with strong clinical data and FDA-aligned pivotal plans.CRBPJefferies Global Healthcare Conference 2026
- Nectin-4 ADCs address a critical gap in HPV-positive oropharyngeal cancer with strong potential.CRBPKOL event
- CRB-701 shows 42.9% ORR in OPSCC and 34.4% in cervical cancer with strong safety profile.CRBPStudy update
Next Corbus Pharmaceuticals earnings date
Jefferies Global Healthcare Conference18 Nov, 2026
Corbus Pharmaceuticals
Next Corbus Pharmaceuticals earnings date
Jefferies Global Healthcare Conference18 Nov, 2026
AI chat
Ask anything. Verify everything.
Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn moreFind what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.)
Trust every finding
50m+ first-party documents. Every output traceable to its source.Find what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.Trust every finding
50m+ first-party documents. Every output traceable to its source.Automations
Zero in on what matters
Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more)
Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.)
Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Live audio & transcripts
Be first
Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more)
Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.)
Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Quartr MCP connects your AI environment to 17K+ public companies
Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more
Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.
Jamie Ross
Investment Manager, GAM Investments
GAM
GAM
Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.
Tom O'Hara
Investment Director
Ciena
Ciena
Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.
Gregg Lampf
VP of Investor Relations
Protean
Protean
Being able to ask specific questions across years of transcripts and reports and instantly get verified answers is a game-changer.
Pontus Dackmo
CEO & Investment Manager
)
)
Frequently asked questions
Corbus Pharmaceuticals Holdings Inc. is a biopharmaceutical company that specializes in precision oncology. The company's research and development efforts focus on innovative treatments that target well-understood biological pathways related to cancer. Corbus' pipeline includes CRB-701, a next-generation antibody-drug conjugate (ADC) designed to target the Nectin-4 protein on cancer cells, and CRB-601, an anti-integrin monoclonal antibody that inhibits the activation of TGFβ on cancer cells. These treatments are intended to combat serious illnesses by offering new therapeutic options for patients. The company is headquartered in Norwood, Massachusetts, and its shares are listed on the NASDAQ.